|Chemical name: Tofacitinib
Typical dosage: 5mg
Typical type: Tablet1
Xeljanz® is a medication typically used to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. It is currently only available as brand name and is available as an oral tablet in immediate release and extended release dosage forms.
Xeljanz is a prescription medication that contains the active ingredient Tofacitinib. It is taken once or twice daily for the chronic treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.
Xeljanz is an immunosuppressant that inhibits Janus kinase enzymes to reduce inflammation, joint damage and other symptoms.
The major side effects of Xeljanz include headache, diarrhea, common cold symptoms, runny nose, sore throat and stuffy nose.
Yes! 69% of Medicare Advantage plans and Medicare Part D plans cover Xeljanz.1
Drug coverage may vary based on plan availability. You may be able to find Medicare Advantage plan options in your area that cover Xeljanz.
Find Medicare Advantage plans with drug coverageCompare Plans
Or call TTY Users: 711 24/7 to speak with a licensed insurance agent.
You can also compare Part D prescription drug plans available where you live and enroll in a Medicare prescription drug plan online when you visit MyRxPlans.com.
Your copay and deductible costs for any prescription drug can vary depending on what coverage stage you’re in.
|Deductible stage||Typical copay stage|
|Your deductible is the amount of money you must spend on covered drugs before your Medicare drug coverage starts paying its share of costs.
In the deductible stage, you’re responsible for the full cost of your prescription drugs.
Some Medicare prescription drug plans have a $0 deductible. Medicare drug plans cannot have a deductible more than $415 in 2019.
|After you meet your Part D deductible, you enter the initial coverage period.
During this phase (the typical copay stage), you pay a copayment (flat fee) or coinsurance (percentage) for your covered medications.
|$1,079 – $5,153||$1,079 – $5,153|
Xeljanz is occasionally used in combination with nonbiologic disease-modifying-antirheumatic drugs (DMARDs) for the treatment of rheumatic and psoriatic arthritis.
While many patients can safely use Xeljanz, it is not currently recommended for women who are pregnant or breastfeeding.
Some patients taking Xeljanz experience serious infections including tuberculosis, shingles, fungal infections and bacterial or viral infections. This risk of infection is increased in patients who take medications that also suppress the immune system, such as methotrexate or corticosteroids.
If you experience any symptoms of infection (fever, chills, sweating, cough, muscle aches, etc.) call your doctor immediately.
You may be evaluated for tuberculosis risk factors or infection before starting Xeljanz, and the presence of tuberculosis may be monitored throughout treatment. Patients with diabetes and/or lung disease should use caution when using Xeljanz because of a higher risk of infection.
Xeljanz may increase your risk of certain cancers – including lymphoma and other skin cancers – by causing changes in your immune system. Renal transplant patients taking Xeljanz have shown an increased rate of Epstein-Barr Virus-associated post-transplant lymphoproliferative disorder.
This article is for informational purposes only. It is not healthcare advice, treatment, or diagnosis. It is not an endorsement of or recommendation for this medication. Speak to your doctor or healthcare provider about your specific healthcare needs, including your prescription medications. Only take medication as directed by your doctor.
Coverage and costs of prescription medications will vary by Medicare plan. Not all plans are available in all areas.
Written by Hayden Gharibyar, Pharm.D.